Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion

摘要

In 2007, a new regimen of once-yearly administration of intravenous (TV) zoledronic acid (Reclast; No-vartis, Basel, Switzerland) for the treatment of osteoporosis was introduced on the Food and Drug Administration's approval. Previous approval had been granted in 2003 for ibandronate (Boniva; Roche Therapeutics, Nutley, NJ) administered parenterally at 3-month intervals.1'2 Although BRONJ has been associated with both IV and oral bisphosphonate treatment, little has been reported on the risk of BRONJ development associated with once yearly or semi-yearly infusions of IV zoledronic acid or ibandronate.3"8 The importance of the use of bisphospho-nates in the treatment of osteoporosis is significant, and the most common treatments in recent years have been based on oral bisphosphonate use. Issues exist with patient noncompliance and inconvenience, highlighting the value of less-frequent treatment regimens such as those of Reclast or Boniva.